Boao Lecheng Publishes 58 Cutting-Edge Medical Technologies Across 13 Disease Areas — Up to RMB 1.4M

Boao Lecheng released a biomedical new-technologies list covering 58 items across 13 disease areas—cell therapy, gene therapy, oncolytic viruses, vaccines, and more—with publicly listed prices from about RMB 16,000 per dose up to RMB 1.4 million per course. Below: indication, receiving institution, and listed price by disease area (confirm in writing with the hospital).

Respiratory diseases (4)

Airway basal-layer stem cell therapy: indication—COPD, interstitial lung disease, bronchiectasis; institution—Ruijin Hospital Hainan (Shanghai Jiao Tong University); listed price—RMB 150,000/dose.

Menstrual-blood MSC therapy for pulmonary fibrosis: indication—Interstitial lung disease; institution—Shulan (Boao) Hospital; listed price—RMB 150,000.

CAStem cell therapy for pulmonary fibrosis: indication—ILD with CT fibrosis; ages 18–75; institution—Boao Super Hospital; listed price—RMB 78,000/session.

MSC/stromal cell therapy for ILD: indication—Interstitial lung disease; institution—Ruijin Hospital Hainan; listed price—RMB 26,500/session.

Degenerative joint disease (3)

Umbilical-cord MSC therapy for knee osteoarthritis: indication—Knee osteoarthritis; institution—Ruijin Hospital Hainan; Hainan Diwan Hospital; listed price—RMB 36,350/session.

M-021001 cell therapy for meniscus injury: indication—Meniscus injury grades I–III; age ≥18; institution—Boao Super Hospital; listed price—RMB 150,000/bag.

CartiLife® autologous chondrocyte repair: indication—Knee cartilage defects (ICRS III/IV, ~2–10 cm²); institution—Boao Super Hospital; listed price—RMB 150,000–195,000/course.

Cardiovascular & cerebrovascular (1)

Umbilical-cord MSC for HFrEF: indication—LVEF ≤40%, NYHA II–IV; institution—West China Lecheng; Boao Fulong CV Hospital; Yiling Life Care Center; listed price—RMB 60,000/session.

Ophthalmology (4)

EXG102-031 gene therapy for wAMD: indication—Wet age-related macular degeneration; institution—Boao Super Hospital; listed price—RMB 100,000/eye.

ZVS101e gene therapy for crystalline retinopathy: indication—CYP4V2 biallelic crystalline retinopathy; institution—Boao Super Hospital; Zhongshan Ophthalmic Center Boao; listed price—RMB 460,000/eye.

FT-003 gene therapy for nAMD: indication—Neovascular AMD; institution—Boao Lecheng Aier Eye Hospital; listed price—RMB 100,000/eye.

Gene therapy for RDH12-related IRD: indication—RDH12-related inherited retinal degeneration; institution—West China Lecheng; Zhongshan Ophthalmic Center Boao; listed price—RMB 480,000/eye.

Oncology prevention & treatment (21)

Personalized antigen-specific immune cell activation: indication—Adjuvant after solid-tumor resection; systemic therapy for unresectable disease; institution—West China Lecheng; listed price—RMB 150,000/injection.

EBV-specific dendritic-cell immunotherapy: indication—EBV-related disease (EBV-DNA >50 copies/mL); institution—West China Lecheng; Boao International; Yingyi IMC; listed price—RMB 16,000/dose.

Autologous DC therapy for pancreatic/colorectal cancer: indication—Pancreatic and colorectal cancer; institution—Boao Super Hospital; listed price—RMB 380,000/course (CRC×3, pancreas×5).

Autologous NK adjunct for solid tumors / relapse prevention: indication—Lung cancer; institution—Shulan (Boao); listed price—RMB 210,000 / 3 sessions.

Autologous NK plus immuno-oncology drugs: indication—Lung, CRC, breast, liver, gastric, ovarian, pancreatic, prostate cancer; institution—West China Lecheng; Boao Future; Meisaier; listed price—RMB 49,800/injection.

EBV mRNA vaccine for EBV-related tumors: indication—EBV-related tumors; institution—West China Lecheng; listed price—RMB 22,000/session.

ScTIL autologous immune cell therapy: indication—Malignancies (solid and hematologic); institution—Boao Super Hospital; listed price—RMB 297,000/session.

Oncolytic virus M1 (VRT106) for advanced HCC / TNBC: indication—Locally advanced or metastatic HCC and TNBC; age ≥18; institution—Shulan (Boao); listed price—RMB 26,550/session.

Oncolytic virus for advanced solid tumors: indication—Advanced solid tumors after ≥1 line failure; institution—Shulan (Boao); listed price—RMB 45,000/session.

Personalized neoantigen vaccine for solid tumors: indication—Adjuvant / consolidation for selected solid tumors; institution—West China Lecheng; listed price—RMB 60,000/dose.

Oncolytic virus hV01 for soft-tissue sarcoma: indication—STS after standard therapy failure; institution—West China Lecheng; listed price—RMB 64,000/course.

Autocrine PD-1 / mesothelin CAR-T for mesothelioma: indication—Mesothelin-positive advanced malignant mesothelioma; institution—Ruijin Hospital Hainan; listed price—RMB 990,000/session.

Autologous PD1-T + XELOX/bevacizumab for advanced CRC: indication—Advanced colorectal cancer; institution—West China Lecheng; listed price—RMB 240,000/session.

Allogeneic CAR-γδT (QH104A) targeting B7-H3: indication—Recurrent/progressive CNS malignancies (e.g. GBM); institution—Boao Super Hospital; listed price—RMB 98,000/session.

Multi-antigen autologous immune cell therapy: indication—Unresectable locally advanced/metastatic STS; ages 18–75; institution—Boao Future Hospital; listed price—RMB 86,850/session.

Autologous RAK after curative HCC resection: indication—Post curative HCC surgery; institution—Ruijin Hospital Hainan; listed price—RMB 45,000/session.

Central memory lymphocyte therapy after HCC resection: indication—Relapse prevention after curative HCC surgery; institution—West China Lecheng; listed price—RMB 120,000/session.

TIL therapy for solid tumors: indication—Malignant melanoma; institution—West China Lecheng; listed price—RMB 65,000/session.

Personalized neoantigen peptide vaccine after pancreatic resection: indication—Post curative pancreatic cancer surgery; institution—Shulan (Boao); listed price—RMB 85,000/session.

Native autologous TIL for lung cancer and melanoma: indication—Cytologically/histologically confirmed lung cancer or melanoma; institution—West China Lecheng; listed price—RMB 79,900/session.

Non-gene-modified DC vaccine for EBV hematologic tumors: indication—EBV-related hematologic malignancies; institution—Ruijin Hospital Hainan; listed price—RMB 126,000/session.

Hematologic diseases (6)

AAV gene therapy for hemophilia A: indication—Congenital FVIII deficiency (hemophilia A); institution—West China Lecheng; listed price—RMB 680,000/session.

Gene-edited autologous HSC for TDT β-thalassemia: indication—Transfusion-dependent β-thalassemia; ages 7–55; institution—Ruijin Hospital Hainan; listed price—TBD.

Gene-modified autologous HSC (KL003) for TDT β-thalassemia: indication—Transfusion-dependent β-thalassemia; institution—West China Lecheng; listed price—RMB 1,400,000/session.

Cell therapy for B-cell NHL: indication—R/R B-cell NHL; age ≥18; institution—Ruijin Hospital Hainan; listed price—RMB 480,000/session.

Autologous HSC gene therapy for TDT β-thalassemia: indication—Transfusion-dependent β-thalassemia; institution—West China Lecheng; listed price—RMB 1,200,000/session.

Autologous CAR-T for R/R CD7+ hematolymphoid malignancies: indication—Adult R/R CD7-positive hematolymphoid malignancies; institution—Ruijin Hospital Hainan; listed price—RMB 1,000,000/session.

Reproductive system (4)

Umbilical-cord MSC for premature ovarian insufficiency: indication—Premature ovarian insufficiency; institution—Ciming Boao International Hospital; listed price—RMB 80,000/session.

Amniotic epithelial stem cells for POF: indication—POF; ages 18–45; institution—Hainan Deya; Qiyan Stem Cell Anti-Aging Hospital; listed price—RMB 58,000/side.

Embryonic stem cell–derived MS-like cells for intrauterine adhesions: indication—Intrauterine adhesions; ages 18–45; institution—Boao Super Hospital; Mumianhua Hospital; listed price—RMB 78,000/session.

Amniotic MSC for diminished ovarian reserve: indication—Diminished ovarian reserve (DOR); institution—Qiyan; Mumianhua; Yiling Life Care Center; listed price—RMB 50,000/session.

Immune diseases (3)

Umbilical-cord MSC for rheumatoid arthritis: indication—Rheumatoid arthritis; institution—West China Lecheng; listed price—RMB 50,000/session.

Umbilical-cord MSC for ankylosing spondylitis: indication—Ankylosing spondylitis; institution—West China Lecheng; listed price—RMB 60,000/session.

Umbilical-cord MSC for SLE: indication—Systemic lupus erythematosus; institution—West China Lecheng; listed price—RMB 135,000/session.

Liver injury (4)

Umbilical-cord MSC (VUM02) for cirrhosis: indication—Cirrhosis; institution—Hainan Meisaier Hospital; listed price—RMB 150,000/session.

Menstrual-blood MSC for decompensated cirrhosis: indication—Decompensated cirrhosis; institution—Shulan (Boao); listed price—RMB 150,000/session.

Allogeneic hepatocyte therapy for cirrhosis: indication—Compensated and decompensated cirrhosis; institution—Boao Super Hospital; listed price—RMB 149,000/session.

Allogeneic bone-marrow MSC for ACLF: indication—Acute-on-chronic liver failure; institution—Boao Super Hospital; listed price—RMB 58,000/session.

Dental diseases (2)

Dental pulp MSC for periodontal disease: indication—Periodontitis meeting radiographic/PD criteria; age ≥18; institution—Hainan Yiling Oral Health Center; listed price—RMB 59,800/tooth.

Dental follicle MSC for periodontitis: indication—Periodontitis; institution—West China Lecheng; listed price—RMB 19,800/tooth.

Endocrine-related (3)

Umbilical-cord MSC for type 2 diabetes: indication—T2DM poorly controlled on ≥3 agents including insulin; institution—Ciming Boao; listed price—RMB 58,000–92,800/injection ×3 (by weight).

Allogeneic EPCs for critical limb ischemia: indication—Severe lower-limb ischemia; institution—West China Lecheng; listed price—RMB 100,000/session.

GLP-1/FGF21 dual-factor adipose stem-cell injection for T2DM: indication—Moderate–severe T2DM poorly controlled; ages 18–70; institution—Ruijin Hospital Hainan; listed price—RMB 360,000/session.

Neurodegenerative disease (2)

iPSC-derived motor neuron precursor therapy for ALS: indication—Amyotrophic lateral sclerosis; institution—Ruijin Hospital Hainan; listed price—RMB 240,000/session.

Gene-modification therapy for SOD1-ALS: indication—ALS with SOD1 mutation; institution—West China Lecheng; listed price—RMB 700,000/session.

Anorectal disease (1)

Adipose MSC plus minimally invasive surgery for complex anal fistula: indication—Complex anal fistula; institution—Ruijin Hospital Hainan; listed price—RMB 79,900/session.

The Boao Lecheng International Medical Tourism Pilot Zone, approved by the State Council in February 2013, pilots franchised medical care, oncology, health management, rehabilitation, and aesthetic medicine—aiming for “three synchronizations” of technology, equipment, and drugs with international standards as China’s only medical-sector opening pilot zone. Prices and indications may change by batch; verify the latest list and admission criteria with the designated hospital before travel.